Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EVMN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| EVO101 | Atopic Dermatitis Eczema | Phase 2 · NCT05579899 | Completed |
| EVO301 | Atopic Dermatitis (AD) | Phase 2 · NCT06723405 | Completed |
| EVO756 | Atopic Dermatitis | Phase 2 · NCT07150845 | Completed |
| EVO756, Dose 1 | Migraine | Phase 2 · NCT07616128 | Recruiting |
| EVO756, Dose 2 | Migraine | Phase 2 · NCT07616128 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
EVMN holds $262.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $23.1M/quarter from operations, an estimated runway of 34.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
We expect that our cash, cash equivalents, and investments as of September 30, 2026, together with the proceeds we received from the Private Placement, will enable us to fund our operating expenses and capital expenditures requirements into the second half of 2029, based on our current business plan.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EVMN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| 7 Cooperative UA LSP Director, 10% owner |
Insider | 5,288,313 | 14.57% | 2026-02-17 |
| Weegen Felice Isabel Verduyn-van Director, 10% owner Includes shares also reported by 7 Cooperative UA LSP, counted once |
Insider | 5,288,313 | 14.57% | 2026-02-17 |
| LSP 7 Cooperatieve U.A. | 5%+ holder (13D) | 5,288,313 | 14.57% | 2026-02-12 |
| RA CAPITAL MANAGEMENT, L.P. Director |
Insider | 3,494,638 | 9.63% | 2026-11-06 |
| Nan Fung Group Holdings Limited | 5%+ holder (13G) | 3,435,599 | 9.47% | 2025-12-31 |
| Robert Lorne Hopfner Director, 10% owner |
Insider | 3,372,001 | 9.29% | 2025-12-19 |
| Point72 Asset Management, L.P. | 5%+ holder (13G) | 2,434,080 | 6.71% | 2026-09-30 |
| Luis C. Pena President & CEO, Director · +291,420 options |
Insider | 631,573 | 1.74% | 2026-09-30 |
| Pivotal bioVenture Partners Fund I, L.P. Director, 10% owner |
Insider | 294,502 | 0.81% | 2025-11-07 |
| Eugene Bauer Chief Medical Officer, Director · +151,117 options |
Insider | 270,818 | 0.75% | 2025-12-09 |
| Janice Suzann Drew Chief of Dev. Operations · +167,008 options |
Insider | 67,794 | 0.19% | 2026-06-22 |
| Gregory S. Moss Chief Business & Legal Officer · +163,124 options |
Insider | 64,010 | 0.18% | 2026-05-28 |
Share count 36,292,113 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EVMN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →